Net Cash Provided by (Used in) Financing Activities of Anixa Biosciences Inc from 31 Oct 2010 to 31 Jan 2026

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Anixa Biosciences Inc quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Oct 2010 to 31 Jan 2026.
  • Anixa Biosciences Inc Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Jan 2026 was $1,685,000.
  • Anixa Biosciences Inc annual Net Cash Provided by (Used in) Financing Activities for 2025 was $2,280,000, a 33% decline from 2024.
  • Anixa Biosciences Inc annual Net Cash Provided by (Used in) Financing Activities for 2024 was $3,415,000, a 833% increase from 2023.
  • Anixa Biosciences Inc annual Net Cash Provided by (Used in) Financing Activities for 2023 was $366,000, a 19% decline from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Anixa Biosciences Inc Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $1,685,000 +$1,702,000 01 Nov 2025 31 Jan 2026 10-Q 09 Mar 2026 2026 Q1
Q4 2024 $17,000 -$2,280,000 -101% 01 Nov 2024 31 Jan 2025 10-Q 09 Mar 2026 2026 Q1
Q4 2023 $2,263,000 +$2,260,000 01 Nov 2023 31 Jan 2024 10-Q 11 Mar 2025 2025 Q1
Q4 2022 $3,000* 01 Nov 2022 31 Jan 2023 10-Q 12 Mar 2024 2024 Q1
Q4 2020 $6,061,000 +$4,280,537 +240% 01 Nov 2020 31 Jan 2021 10-Q 11 Mar 2022 2022 Q1
Q4 2019 $1,780,463 -$395,821 -18% 01 Nov 2019 31 Jan 2020 10-Q 11 Mar 2021 2021 Q1
Q4 2018 $2,176,284 01 Nov 2018 31 Jan 2019 10-Q 09 Mar 2020 2020 Q1
Q4 2016 $494,335 01 Nov 2016 31 Jan 2017 10-Q 09 Mar 2018 2018 Q1
Q4 2013 $3,500,000 +$1,735,000 +98% 01 Nov 2013 31 Jan 2014 10-Q 09 Mar 2015 2015 Q1
Q4 2012 $1,765,000 +$1,617,750 +1099% 01 Nov 2012 31 Jan 2013 10-Q 17 Mar 2014 2014 Q1
Q4 2011 $147,250 -$330,600 -69% 01 Nov 2011 31 Jan 2012 10-Q/A 25 Mar 2013 2013 Q1
Q4 2010 $477,850 01 Nov 2010 31 Jan 2011 10-Q 16 Mar 2012 2012 Q1

Anixa Biosciences Inc Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $2,280,000 -$1,135,000 -33% 01 Nov 2024 31 Oct 2025 10-K 12 Jan 2026 2025 FY
2024 $3,415,000 +$3,049,000 +833% 01 Nov 2023 31 Oct 2024 10-K 12 Jan 2026 2025 FY
2023 $366,000 -$86,000 -19% 01 Nov 2022 31 Oct 2023 10-K 10 Jan 2025 2024 FY
2022 $452,000 -$31,114,000 -99% 01 Nov 2021 31 Oct 2022 10-K 16 Jan 2024 2023 FY
2021 $31,566,000 +$22,159,102 +236% 01 Nov 2020 31 Oct 2021 10-K 04 Jan 2023 2022 FY
2020 $9,406,898 +$3,704,280 +65% 01 Nov 2019 31 Oct 2020 10-K 04 Jan 2022 2022 FY
2019 $5,702,618 +$3,174,298 +126% 01 Nov 2018 31 Oct 2019 10-K 07 Jan 2021 2020 FY
2018 $2,528,320 -$4,854,629 -66% 01 Nov 2017 31 Oct 2018 10-K 09 Jan 2020 2019 FY
2017 $7,382,949 +$7,385,625 01 Nov 2016 31 Oct 2017 10-K 11 Jan 2019 2018 FY
2016 $2,676* +$397,942 01 Nov 2015 31 Oct 2016 10-K 09 Jan 2018 2017 FY
2015 $400,618 -$7,749,637 -105% 01 Nov 2014 31 Oct 2015 10-K 08 Dec 2016 2016 FY
2014 $7,349,019 +$4,103,066 +126% 01 Nov 2013 31 Oct 2014 10-K 23 Dec 2015 2015 FY
2013 $3,245,953 +$2,287,503 +239% 01 Nov 2012 31 Oct 2013 10-K 29 Jan 2015 2014 FY
2012 $958,450 -$1,575,650 -62% 01 Nov 2011 31 Oct 2012 10-K/A 17 Jan 2014 2013 FY
2011 $2,534,100 +$1,285,100 +103% 01 Nov 2010 31 Oct 2011 10-K 29 Jan 2013 2012 FY
2010 $1,249,000 01 Nov 2009 31 Oct 2010 10-K 30 Jan 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.